[1] |
WANG F,XU RH,HAN B,et al.High incidence of hepatitis B virus infection in B-cell subtype non-Hodgkin lymphoma compared with other cancers[J].Cancer,2007,109(7):1360. |
[2] |
CHEN MH,HSIAO LT,CHIOU TJ,et al.High prevalence of occult hepatitis B virus infection in patients with B cell non-Hodgkin's lymphoma[J].Ann Hematol,2008,87(6):475. |
[3] |
刘卫平,郑文.王小沛,等.405例非霍奇金淋巴瘤患者乙型肝炎病毒感染率分析[J].中华血液学杂志,2011,32(8):521. |
[4] |
Liver EAFTSOT.Corrigendum to:"EASL clinical practice guidelines:Management of chronic hepatitis B virus infection"[J].J Hepatol,2012,57(1):167. |
[5] |
YEO W,CHAN PK,ZHONG S,et al.Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemo-therapy:aprospective study of 626 patients with identification of risk factors[J].J Med Virol,2000,629(3):209. |
[6] |
郭海鹰,王小渝.乙肝病毒感染的恶性淋巴瘤患者化疗后肝功能衰竭死亡3例及文献复习[J].华西医学,2008,23(2):345. |
[7] |
YEO W,HUI EP,CHAN AT,et al.Prevention of hepatitis B virus reactivation in patients with nasopharyngeal carcinoma with lamivudine[J].Am J Clin Oncol,2005,28(4):379. |
[8] |
CHOU CK,WANG LH,LIN HM,et al.Glucocorticoid stimulates hepatitis B viral gene expression in cultured human hepatoma cells[J].Hepatology,1992,16(1):13. |
[9] |
CHENG AL,HSIUNG CA,SU IJ,et al.Steroid-free chemotherapy decreases risk of hepatitis B virus(HBV) reactivation in HBV-carriers with lymphoma[J].Hepatology,2003,37(6):1320. |
[10] |
李军民.《淋巴瘤合并HBV感染患者管理中国专家共识》解读[J].中华血液学杂志,2014,35(4):371. |
[11] |
黄晶,陈小苹,陈学福,等.拉米夫定及恩替卡韦预防和治疗非霍奇金淋巴瘤相关性HBV再激活的疗效对比[J].实用医学杂志,2011,27(12):2225. |
[12] |
倪传斌,龙波.拉米夫定及恩替卡韦预防和治疗非霍奇金淋巴瘤相关性HBV再激活的疗效对比[J].临床肝胆病杂志,2014,30(4):363. |
[13] |
谭英,吴惠芳,邹萌丽,等.拉米夫定及恩替卡韦治疗非何杰金淋巴瘤相关性HBV再激活的对照研究[J].江西医药,2014,49(9):854. |